Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2025 06:06 ET | Source: Karolinska Development AB (publ)

Karolinska Development investerar 7,5 miljoner SEK för att stödja BOOST Pharmas fortsatta utveckling av BT-101 mot klinisk fas 3

STOCKHOLM, SVERIGE - 28 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att bolaget har deltagit med sin pro rata-andel om 7,5 miljoner kronor i portföljbolaget BOOST...
October 28, 2025 06:06 ET | Source: Karolinska Development AB (publ)

Karolinska Development invests SEK 7.5 million to support BOOST Pharma’s continued development of BT-101 towards Phase 3

Stockholm, Sweden – October 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that it has exercised its pro rata participation of SEK 7.5 million in BOOST Pharma’s latest...
October 24, 2025 02:45 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag SVF Vaccines presenterar positiva data från en preklinisk studie med SVF-001 inom kronisk hepatit B och D

STOCKHOLM, 24 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines har presenterat positiva resultat från en preklinisk studie med bolagets...
October 24, 2025 02:45 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company SVF Vaccines presents positive data from a preclinical study of SVF-001 in chronic hepatitis B and D

STOCKHOLM, Sweden, October 24, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented positive results from a preclinical study of its...
October 09, 2025 13:24 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag PharmNovo får godkännande att inleda en fas 2a-studie med läkemedelskandidaten PN6047 i Spanien

STOCKHOLM, SVERIGE 9 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget PharmNovo fått godkänt av spanska myndigheter att inleda en klinisk fas 2a-studie med...
October 09, 2025 13:24 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain

STOCKHOLM, SWEDEN – October 9, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company PharmNovo has received approval from the Spanish regulatory...
October 03, 2025 02:30 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Dilafor beviljas patent i USA för tafoxiparin vid initiering av spontan förlossning

STOCKHOLM, 3 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Dilafor beviljats ett patent i USA som skyddar bolagets läkemedelskandidat tafoxiparin...
October 03, 2025 02:30 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Dilafor receives patent in the US for tafoxiparin in priming of labor

STOCKHOLM, SWEDEN – October 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has been granted a patent in the US protecting its drug...
September 16, 2025 03:05 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag AnaCardio har slutfört rekryteringen i sin fas 2a-studie med läkemedelskandidaten AC01

STOCKHOLM, SVERIGE 16 september 2025 Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardio har slutfört patientrekryteringen i fas 2a-delen av den kliniska...
September 16, 2025 03:05 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company AnaCardio completes patient recruitment in phase 2a study of its drug candidate AC01

STOCKHOLM, SWEDEN September 16, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed enrollment in the phase 2a part of its...